In this area you will be able to:
- Propose, vote on, and discuss research ideas
- View current studies
- View published research
Here, you can submit a research idea to the community, cast your votes, and discuss research ideas proposed by other members. Please make your research question as specific as possible. Other members will vote on your research idea, and we will prioritize research ideas with the most votes.
You are allowed to vote for your own proposed research idea if you want. However, you can only vote for a total of five research ideas. If you have already cast your five votes and an idea you like even more is proposed, you can change your votes at any time to reflect your current preferences.
The research team will review all submitted ideas and provide a response to you and to the community. If your idea leads to an IBD Partners Study, you will have the opportunity to serve as a patient collaborator on the research team for that study.
We encourage you to prioritize the ideas that are most important to you, even if the research team determines that your idea is not a good fit for IBD Partners. We will share ideas labeled “Not a Good Fit” with researchers outside of our network when appropriate. We want to make sure all of your votes count!
Thanks for your participation in this important platform to help the IBD research community understand what research questions are important to patients. We are passionate about finding answers to your questions!
Several studies have already been done in Israel at the Meir Institute with very promising results. A placebo controlled study with medication-resistant patients showed a remission rate approximately the same as leading medications. (~50% clinical remission.) Creating safer medications that are also less expensive than current medications should be a high priority, particularly given the promising results, both clinical and anecdotal, and the rising approval of medical cannabis across the US.
I would like more research done on using the combination of a biologic (Humira) and Azathioprine (Imuran) together for treatment of crohns. Are the benefits really worth the risk? or is the risk not that bad?
I am on both of these meds and I have been questioned by my pharmacist about taking both of them together. I have read about the risks, and I'm not sure if I really do need both of the drugs. The information I have read seems to imply that getting cancer at some point is almost a certainty.
We know that Jews of European decent have a much higher chance of having an IBD. We know that the number of diagnosis of IBD has risen significantly in the last few decades. What is the one huge event that happened to the Jews of Europe just 70 years ago? The Holocaust. It could be a gene that was associated with another gene that promoted survival. It could have been a gene mutation due to living in extreme conditions. It could have been the terrible sanitation. It could have been the trauma that had been passed on to the following generations... there is much to investigate there. I come from a family of Holocaust survivors, myself. Thank you for your consideration.
How can the sCDAI be accurately assessed for Crohn's patients who experience constipation and not frequent and/or loose bowel movements?
Diarrhoea is not a symptom in all Crohn's patients. This causes two primary issues. The first issue is the length of time to be tested and diagnosed as constipation is not often seen as a symptom. Second, most disease activity surveys/charts/measurements become inaccurate for those who do not experience loose, watery stools. This only adds to the frustration and alienation of the patient from society and now their own IBD community.
Research tends to focus on negative emotional state (depression) and the potential downside. Work by Dr B. Fredrickson shows positive emotions can provide favorable health impact and has developed a simple on line tool to measure positive emotions which could be incorporated into this site to do research going forward.
Sequence the DNA of components of patients' microbiomes to find any associations with variables like severity of symptoms, location of disease, extra-intestinal manifestations and response to medications.
The 'genome' of a patient's microbiome could provide guidance in treating with specific medications and/or probiotics.
What pain treatment options (pharmacologic or otherwise) do IBD patients find most effective, and what are the risks associated with these treatments.
Many pain medications are addictive and/or harmful, particularly in IBD patients. Pain is a common symptom of IBD. I would like to explore patient experiences of the efficacy of pain treatments including: acupunctue, message therapy, heat therapy, NSAIDs, acetaminophen, SNRI antidepressants, tramadol, opiate pain medications. Either through literature review or additional research, it would be valuable to see a comprehensive review of risks and benefits of common pain treatments specific to use in IBD patients.
Diet Low in Red and Processed Meat Does Not Reduce Rate of Crohn’s Disease Flares
Impact of Obesity on Disease Activity andPatient-Reported Outcomes Measurement InformationSystem (PROMIS) in Inflammatory Bowel Diseases